BioCryst Pharmaceuticals, Inc.
BCRXNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 15, 2026 close
- Market cap
- $2.13B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $6.23$11.22
- Volume (live)
- -
- Avg. volume (3M)
- 5.26M
BioCryst Pharmaceuticals (BCRX) Stock Price & Financial Analysis
BioCryst Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $7.95 - $8.24 |
|---|---|
| 52-Week High | $11.22 |
| 52-Week Low | $6.23 |
| Open | $8.11 |
| Volume (last close) | 4.50M |
| Average Volume (3M) | 5.26M |
| Revenue (TTM) | 940.61M |
|---|---|
| Net Income (TTM) | -384.67M |
| Free Cash Flow (TTM) | 357.11M |
| EPS (TTM) | −$1.63 |
| Profit Margin | -40.90% |
| Operating Margin | -33.29% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 2.13B |
|---|---|
| Shares Outstanding | 265.17M |
| Price to Sales (P/S) | 2.26 |
| Price to Book (P/B) | -4.68 |
| EV/EBITDA | 6.98 |
| 50-Day MA | $9.05 |
|---|---|
| 200-Day MA | $8.71 |
| 1-Year Change | +19.35% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
BioCryst Pharmaceuticals at a Glance
As of the Oct 15, 2026 close, BioCryst Pharmaceuticals (BCRX) has a market capitalization of $2.13B. The stock trades at 2.3× sales. Over the trailing twelve months it lost $384.67M on revenue of $940.61M and generated $357.11M of free cash flow. Revenue grew 68.7% year over year.
As of its latest reported balance sheet, it holds $154.97M in cash and securities against $781.38M of debt, a net debt position of $626.41M.
BioCryst Pharmaceuticals does not currently pay a dividend.
The share price is up 19.3% over the past year. At $8.02 (the Oct 15, 2026 close) it sits within its 52-week range of $6.23 to $11.22, below its 200-day moving average of $8.71.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $19.25, 140.0% above the Oct 15, 2026 close.
Frequently Asked Questions About BioCryst Pharmaceuticals
What is the current stock price for BCRX?
As of the Oct 15, 2026 close, BCRX stock trades at $8.02. The 52-week range is $6.23–$11.22, with a day range of $7.95–$8.24.
What is the P/E ratio for BCRX?
The P/E ratio (Price-to-Earnings) for BCRX is shown in the Key Statistics section. This valuation metric helps compare BioCryst Pharmaceuticals, Inc. to industry peers.
Does BCRX pay dividends?
BioCryst Pharmaceuticals does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BCRX?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for BCRX is Buy. The average 12-month price target is $19.25, a 140.0% upside from the Oct 15, 2026 close of $8.02.
What is the market cap of BCRX?
As of the Oct 15, 2026 close, BioCryst Pharmaceuticals's market capitalization is $2.13B, classifying it as a mid-cap company. BioCryst Pharmaceuticals operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.